Literature DB >> 17427204

Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring.

Peter F Thall1, Leiko H Wooten, Christopher J Logothetis, Randall E Millikan, Nizar M Tannir.   

Abstract

For many diseases, therapy involves multiple stages, with the treatment in each stage chosen adaptively based on the patient's current disease status and history of previous treatments and clinical outcomes. Physicians routinely use such multi-stage treatment strategies, also called dynamic treatment regimes or treatment policies. We present a Bayesian framework for a clinical trial comparing two-stage strategies based on the time to overall failure, defined as either second disease worsening or discontinuation of therapy. Each patient is randomized among a set of treatments at enrollment, and if disease worsening occurs the patient is then re-randomized among a set of treatments excluding the treatment received initially. The goal is to select the two-stage strategy having the largest average overall failure time. A parametric model is formulated to account for non-constant failure time hazards, regression of the second failure time on the patient's first worsening time, and the complications that the failure time in either stage may be interval censored and there may be a delay between first worsening and the start of the second stage of therapy. Four different criteria, two Bayesian and two frequentist, for selecting a best strategy are considered. The methods are applied to a trial comparing two-stage strategies for treating metastatic renal cancer, and a simulation study in the context of this trial is presented. Advantages and disadvantages of this design compared to standard methods are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17427204     DOI: 10.1002/sim.2894

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  28 in total

1.  Dynamic treatment regimes for managing chronic health conditions: a statistical perspective.

Authors:  Bibhas Chakraborty
Journal:  Am J Public Health       Date:  2010-11-18       Impact factor: 9.308

Review 2.  A review of phase 2-3 clinical trial designs.

Authors:  Peter F Thall
Journal:  Lifetime Data Anal       Date:  2007-09-02       Impact factor: 1.588

3.  Developing and testing adaptive treatment strategies using substance-induced psychosis as an example.

Authors:  Ree Dawson; Alan I Green; Robert E Drake; Thomas H McGlashan; Bella Schanzer; Philip W Lavori
Journal:  Psychopharmacol Bull       Date:  2008

4.  Reinforcement learning design for cancer clinical trials.

Authors:  Yufan Zhao; Michael R Kosorok; Donglin Zeng
Journal:  Stat Med       Date:  2009-11-20       Impact factor: 2.373

5.  Semiparametric Single-Index Model for Estimating Optimal Individualized Treatment Strategy.

Authors:  Rui Song; Shikai Luo; Donglin Zeng; Hao Helen Zhang; Wenbin Lu; Zhiguo Li
Journal:  Electron J Stat       Date:  2017       Impact factor: 1.125

Review 6.  Recent development on statistical methods for personalized medicine discovery.

Authors:  Yingqi Zhao; Donglin Zeng
Journal:  Front Med       Date:  2013-02-02       Impact factor: 4.592

7.  A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes.

Authors:  Thomas A Murray; Ying Yuan; Peter F Thall
Journal:  J Am Stat Assoc       Date:  2018-10-08       Impact factor: 5.033

8.  Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes.

Authors:  Phillip J Schulte; Anastasios A Tsiatis; Eric B Laber; Marie Davidian
Journal:  Stat Sci       Date:  2014-11       Impact factor: 2.901

Review 9.  Inference for non-regular parameters in optimal dynamic treatment regimes.

Authors:  Bibhas Chakraborty; Susan Murphy; Victor Strecher
Journal:  Stat Methods Med Res       Date:  2009-07-16       Impact factor: 3.021

10.  Penalized Q-Learning for Dynamic Treatment Regimens.

Authors:  R Song; W Wang; D Zeng; M R Kosorok
Journal:  Stat Sin       Date:  2015-07       Impact factor: 1.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.